London · Delayed Price · Currency is GBP · Price in GBX CelLBxHealth Statistics
Total Valuation
CelLBxHealth has a market cap or net worth of GBP 14.49 million. The enterprise value is 12.93 million.
| Market Cap | 14.49M |
| Enterprise Value | 12.93M |
Important Dates
The next estimated earnings date is Monday, September 7, 2026.
| Earnings Date | Sep 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CelLBxHealth has 1.14 billion shares outstanding. The number of shares has increased by 135.82% in one year.
| Current Share Class | 1.14B |
| Shares Outstanding | 1.14B |
| Shares Change (YoY) | +135.82% |
| Shares Change (QoQ) | +195.16% |
| Owned by Insiders (%) | 16.81% |
| Owned by Institutions (%) | 32.74% |
| Float | 491.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.58 |
| PB Ratio | 3.53 |
| P/TBV Ratio | 3.77 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.22 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.54, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.54 |
| Quick Ratio | 2.07 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.15 |
| Interest Coverage | -68.28 |
Financial Efficiency
Return on equity (ROE) is -163.78% and return on invested capital (ROIC) is -46.39%.
| Return on Equity (ROE) | -163.78% |
| Return on Assets (ROA) | -37.24% |
| Return on Invested Capital (ROIC) | -46.39% |
| Return on Capital Employed (ROCE) | -227.45% |
| Weighted Average Cost of Capital (WACC) | 6.95% |
| Revenue Per Employee | 10,105 |
| Profits Per Employee | -113,526 |
| Employee Count | 119 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 1.09 |
Taxes
In the past 12 months, CelLBxHealth has paid 597,000 in taxes.
| Income Tax | 597,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.75% in the last 52 weeks. The beta is 0.43, so CelLBxHealth's price volatility has been lower than the market average.
| Beta (5Y) | 0.43 |
| 52-Week Price Change | -78.75% |
| 50-Day Moving Average | 1.55 |
| 200-Day Moving Average | 1.32 |
| Relative Strength Index (RSI) | 35.59 |
| Average Volume (20 Days) | 1,520,739 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CelLBxHealth had revenue of GBP 1.15 million and -12.94 million in losses. Loss per share was -0.02.
| Revenue | 1.15M |
| Gross Profit | -333,000 |
| Operating Income | -7.71M |
| Pretax Income | -12.35M |
| Net Income | -12.94M |
| EBITDA | -6.77M |
| EBIT | -12.22M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 2.88 million in cash and 1.31 million in debt, with a net cash position of 1.56 million or 0.00 per share.
| Cash & Cash Equivalents | 2.88M |
| Total Debt | 1.31M |
| Net Cash | 1.56M |
| Net Cash Per Share | 0.00 |
| Equity (Book Value) | 4.11M |
| Book Value Per Share | 0.00 |
| Working Capital | 3.75M |
Cash Flow
In the last 12 months, operating cash flow was -8.66 million and capital expenditures -162,000, giving a free cash flow of -8.83 million.
| Operating Cash Flow | -8.66M |
| Capital Expenditures | -162,000 |
| Depreciation & Amortization | 1.61M |
| Net Borrowing | -753,000 |
| Free Cash Flow | -8.83M |
| FCF Per Share | -0.01 |
Margins
| Gross Margin | -28.91% |
| Operating Margin | -669.53% |
| Pretax Margin | -1,071.61% |
| Profit Margin | n/a |
| EBITDA Margin | -587.50% |
| EBIT Margin | -1,061.02% |
| FCF Margin | n/a |
Dividends & Yields
CelLBxHealth does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -135.82% |
| Shareholder Yield | -135.82% |
| Earnings Yield | -89.32% |
| FCF Yield | -60.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CelLBxHealth has an Altman Z-Score of -27.89 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -27.89 |
| Piotroski F-Score | 1 |